| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 4, 2025 5:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)
EFFECT - Hoth Therapeutics, Inc. (0001711786) (Filer)
424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
3 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.Safety and tolerability findings included:No serious adverse events (0%)No dose-limiting toxicities observed.No treatment discontinuations due to adverse eventsDay 42 Data Show Higher AUC, Cavg, and Cmax vs Day 1, with ~2.1x Accumulation Supporting Sustained Drug Exposure, Consistent Tolerability, and Clinically Meaningful ResponseNEW YORK, March 24, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) today reported positive pharmacokinetic (PK), safety, and clinical activity data for HT-001, demonstrating a ~77% increase in systemic drug expos
HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment preserved hepatic autophagy and maintained normal liver cellular homeostasisFindings support continued development of HT-VA for metabolic dysfunction associated with obesity and MASLDNEW YORK, March 10, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs, today announced new female-specific preclinical results from the second phase of its metabolic disease study evaluating glial cell-derived neurotrophic factor (G
AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven CancersNEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers. The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of K
4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies. These common treatment-limiting side effects—suc
NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)
SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)